Navigation Links
Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma
Date:5/5/2009

aiming to evaluate the safety and the efficacy of the product.

"With this fourth pharmaceutical product entering in clinical development, Novagali completes its late stage product pipeline" said Jerome Martinez, president and CEO of Novagali Pharma. "We expect Catioprost(R) to bring significant safety and comfort improvement for glaucoma patients, especially for those suffering from ocular surface diseases."

About Novagali Pharma : http://www.novagali.com

Novagali Pharma is an ophthalmic pharmaceutical company that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), for treatment of vernal keratoconjunctivitis, Cyclokat(R), for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma is based in the Genopole biocluster in Evry (France).

In 2009, Frost & Sullivan recognized Novagali with the North American Award for Industry Innovation & Advancement of the Year, for its two proprietary emulsion technology platforms, Novasorb(R) and Eyeject(R).


'/>"/>
SOURCE Novagali Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
2. Novagali Pharma Completes a EUR15 Million Fund Raising
3. Novagali Pharma Announces the Launch of Cationorm(R)
4. Fifth Annual SemTech Conference Highlights How Semantics Power Chemistry, Pharmaceutical, Healthcare, and Other Life Science Solutions
5. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
6. Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
7. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
8. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
9. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
10. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
11. Idenix Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 Global Stem Cells ... plans for the company’s first cellular and regenerative medicine ... a full day, hands-on stem cell training class Oct. ... Garcia Gimenez, M.D., President of Therapeutic Confrontations (CONFTERA) in ... increasing interest in regenerative medicine and recent advances in ...
(Date:5/26/2015)... Texas , May 26, 2015  A simple ... Health Science Center to detect early Alzheimer,s disease is ... adults. Detailed standardized guidelines that are needed ... have been published in Alzheimer,s & Dementia . ... of an international working group that includes UNT Health ...
(Date:5/26/2015)... mája 2015 Kevin Xu , ... prezidentom Barackovi Obamovi a Billovi Clintonovi za ich ... Dr. Rongxiang Xu , otca Kevina. ... Dr. Xu bol pionier, inovátor, humanitárny pracovník ... v oblasti vedy a príkladné vedenie svojej komunity ...
(Date:5/26/2015)... 26, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... study protocol for the company,s Phase IIb trial of ... and Drug Administration (FDA). The submission was made under ... The Phase IIb study of ORMD-0801 for type ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... Therapeutics,(Nasdaq: NKTR ) today announced that ... pulmonary delivery assets, technology, and intellectual,property to Novartis ... completed,on December 31, 2008. , ... certain dry powder and,liquid pulmonary formulation and manufacturing ...
... to announce the 3rd Global Jatropha Hi-Tech Agricultural Training Programme ... privilege to provide most authoritative Knowledge platform known as Global ... Jatropha Oil Crop Projects, Programmes and Priorities to Feed Biodiesel ... ...
... Merial, a world leading animal health,company, and the ... Merial to obtain exclusive rights to Imugene vector,technology. ... the product development process to global sales. Additional ... and, if successful, will,also progress into the product ...
Cached Biology Technology:Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million 2CJP Declares the Dates of 3rd Global Jatropha Hi-Tech Agricultural Training Programme 2CJP Declares the Dates of 3rd Global Jatropha Hi-Tech Agricultural Training Programme 3CJP Declares the Dates of 3rd Global Jatropha Hi-Tech Agricultural Training Programme 4Imugene and Merial Establish Strategic Alliance 2
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint Cards ... FPC1025 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... be used by smartphone manufacturers in China ... the communicated revenue guidance of + 1 000 MSEK for 2015. ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a ... established helmet producer, announced today that they will expand ... the world,s first bio-sensing cycling helmet and the first ... in two new colors in order to give cyclists ... product. In addition, LifeBEAM and Lazer announced their plan ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... University School of Medicine has helped confirm the reliability ... ushering in the long-promised era of personalized medicine based ... one of the five sites that helped determine that ... risk of developing cirrhosis from chronic hepatitis C infection. ...
... hospitals in Peru has shown that opening windows and ... ventilated negative-pressure rooms and 18 times that of rooms ... led by Rod Escombe from Imperial College London, compared ... as respiratory isolation rooms, TB wards, respiratory wards, general ...
... called lupus, is a complex autoimmune disease marked ... depression, among other symptoms. Some studies have described ... manifestation, psychosis, and a protein autoantibody associated with ... , To investigate how an autoantibody could stimulate ...
Cached Biology News:New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3New insights into autoimmunity and depression 2